Intervention
ADVERSE EVENTS, COMPLICATIONS
A thorough and organized history was obtained from the patients who met the criteria to participate in the study. Additionally, they received a particular informed consent form to acquaint them with the research objectives and were categorized into three groups regarding gestational age. The first group of patients was designated to be the control group. It was given misoprostol 200 mg (Misoglandin, Samisaz Co, Mashhad, Iran) every 6 h sublingually and three suppositories through the posterior vaginal fornix per night [The second and third groups followed different medication regimes as their treatment. In the second group, misoprostol 200 mg was prescribed in the form of sublingual tablet intake every 6 h and three suppositories through the posterior vaginal fornix combined with intramuscular methylergometrine 0.2 mg (Minoo Co, Tehran, Iran) thrice a day. These groups were also advised to refer to the closest clinic to take the injection cautiously [On the other hand, the third group was prescribed misoprostol 200 mg sublingually every 6 h and three suppositories through the posterior vaginal fornix every night. Also, this group was simultaneously administered oxytocin (Vetocin, Aburaihan Pharma Co., Tehran, Iran), 30 units in the morning and 30 units intramuscularly in the afternoon. It was advised to refer to the nearest healthcare center for these injections [Likewise, in those patients with negative Rh, an intramuscular Rhogam 300 mg injection was prescribed to prevent iso-immunization [Participants in all three study arms received education on potential side effects to ensure the safe use of oxytocin and other regimes in the outpatient setting. They were instructed to report any adverse events promptly to the gynecology and obstetrics clinic affiliated with Jahrom University of Medical Sciences. The clinic was well-equipped to handle potential complications, and participants were fully monitored throughout the study. These safety measures were implemented to minimize the risks associated with outpatient use of oxytocin.